Indegene Limited is a digital-first, life sciences commercialization company that partners with biopharmaceutical, emerging biotech, and medical device companies. Its focus lies in developing products, accelerating their market entry, and driving impact throughout the product lifecycle. Indegene achieves this through healthcare domain expertise, fit-for-purpose technology, and an agile operating model, enabling businesses to modernize their approaches effectively.
On Tuesday, December 3, Indegene’s share price traded 5.73% lower at ₹628.80 per share on the NSE. Despite this decline, the stock has shown robust growth over the past six months, gaining 25.09%. The company’s performance has been noteworthy since its listing earlier this year.
Two substantial block deals were recently reported in Indegene shares:
These transactions underscore significant market activity and investor interest in the stock.
As per the September quarter data, the major shareholders in Indegene include:
This diversified ownership indicates strong institutional backing and investor confidence in Indegene’s business model.
Indegene Limited made its debut on the stock exchanges on May 13, 2024, with an impressive premium of 46% over its issue price of ₹452.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.
We're Live on WhatsApp! Join our channel for market insights & updates